Panel Discussion: Acting on Molecular Progression to Improve Therapeutic Decision Making Before Imaging Detects Resistance

9:30 am - Thursday 18th March 2027

  • Determining how much molecular change justifies a switch when the scan still reads stable
  • Weighing the risk of switching too early against the cost of waiting for radiographic confirmation
  • Establishing what evidence oncologists and payers need before molecular progression becomes an accepted trigger

Speakers:

Executive Director & Head, Precision Medicine
Bristol Myers Squibb
Global Head, Diagnostics
Amgen
Senior Director, Oncology Precision Medicine
Regeneron Pharmaceuticals
Principal Scientific Manager
Genentech